Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular benefits for selected patients without diabetes who have established heart disease, but further price reductions are needed to make the therapy good value for money, according to a new analysis from researchers at Beth Israel Deaconess Medical Center (BIDMC).
This article was originally published on MedicalXpress.com
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
© 2025 SimplyWell.ca